Clinical Study
Efficacy of Ingenol Mebutate in the Treatment of Actinic Keratoses: A Pre- and Posttreatment Dermoscopic Comparative Analysis
Table 1
Study population and efficacy data, related to clinical and dermoscopic response.
| | Variable | Clinical response | P-value | Dermoscopic response | P-value | Total | | Poor | Partial/Complete | Poor | Partial/Complete |
| | Age | 80 ± 4.8 | 75.7 ± 6.9 | 0.099 | 77.7 ± 4.8 | 76.1 ± 7.1 | 0.535 | 76.4 ± 6.7 |
| | 7.3 ± 2.4 | 6 ± 4.3 | 0.442 | 5.1 ± 2.4 | 6.5 ± 4.3 | 0.365 | 6.2 ± 4 |
| | VAS | 2.8 ± 2.4 | 4.3 ± 2.3 | 0.095 | 3.6 ± 2.6 | 4.2 ± 2.4 | 0.496 | 4.1 ± 2.4 |
| | Gender | | | 0.7522 | | | 0.6157 | |
| | Male | 7 (17.5%) | 33 (82.5%) | | 8 (20%) | 32 (80%) | | 40 (100%) |
| | Female | 1 (8.3%) | 11 (91.7%) | | 1 (8.3%) | 11 (91.7%) | | 12 (100%) |
| | Lesion site | | | 0.3245 | | | 0.0048 | |
| | Face | 3 (11.1%) | 24 (88.9%) | | 1 (3.7%) | 26 (96.3%) | | 27 (100%) |
| | Scalp | 5 (23.8%) | 16 (76.2%) | | 8 (38.1%) | 13 (61.9%) | | 21 (100%) |
| | Trunk & extremities | 0 (0%) | 4 (100%) | | 0 (0%) | 4 (100%) | | 4 (100%) |
| | Pre-treatment clinical grade | | | 0.3802 | | | 0.6325 | |
| | I | 0 (0%) | 4 (100%) | | 0 (0%) | 4 (100%) | | 4 (100%) |
| | II | 3 (11.5%) | 23 (88.5%) | | 5 (19.2%) | 21 (80.8%) | | 26 (100%) |
| | III | 5 (22.7%) | 17 (77.3%) | | 4 (18.2%) | 18 (81.8%) | | 22 (100%) |
| | Pre-treatment dermoscopic grade | | | 0.2669 | | | 0.0232 | |
| | I | 2 (16.7%) | 10 (83.3%) | | 5 (41.7%) | 7 (58.3%) | | 12 (100%) |
| | II | 0 (0%) | 11 (100%) | | 0 (0%) | 11 (100%) | | 11 (100%) |
| | III | 6 (20.7%) | 23 (79.3%) | | 4 (13.8%) | 25 (86.2%) | | 29 (100%) |
| | Total n of patients | 8 (15.4%) | 44 (84.6%) | | 9 (17.3%) | 43 (82.7%) | | 52 (100%) |
|
|
LSR, local skin reaction; VAS, visual analogue scale.
|
